Disclaimer: This is a user generated content submitted by a member of the WriteUpCafe Community. The views and writings here reflect that of the author and not of WriteUpCafe. If you have any complaints regarding this post kindly report it to us.

The Ovarian Cancer Diagnostics Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Ovarian Cancer Diagnostics Market:
https://www.thebusinessresearchcompany.com/report/ovarian-cancer-diagnostics-global-market-report

According to The Business Research Company’s Ovarian Cancer Diagnostics Global Market Report 2024, The ovarian cancer diagnostics market size has grown strongly in recent years. It will grow from $2.62 billion in 2023 to $2.82 billion in 2024 at a compound annual growth rate (CAGR) of 7.6%.  The  growth in the historic period can be attributed to growth in biomarker discovery and validation, transvaginal ultrasound adoption, brca gene mutations awareness, research on tumor markers, screening programs and guidelines.

The ovarian cancer diagnostics market size is expected to see strong growth in the next few years. It will grow to $3.65 billion in 2028 at a compound annual growth rate (CAGR) of 6.7%.  The growth in the forecast period can be attributed to early detection initiatives, increasing incidence of ovarian cancer, integration of artificial intelligence (ai), personalized medicine approaches, emergence of novel biomarkers, genomic and proteomic profiling. Major trends in the forecast period include biosensor technologies for early detection, digital pathology integration, innovations in imaging modalities, improved imaging technologies, advancements in pathology techniques.

The rise in the prevalence of ovarian cancer is expected to propel the growth of the ovarian cancer diagnostics market going forward. Ovarian cancer is a malignant tumor that develops in the ovaries, the female reproductive organs responsible for producing eggs and hormones. This shift has resulted from increased longevity, delayed childbearing, and lifestyle changes. Ovarian cancer diagnostics can help reduce the prevalence of ovarian cancer by enabling early detection and intervention, leading to timely treatment and improved outcomes. For instance, in February 2022, according to the World Ovarian Cancer Coalition, a Canada-based not-for-profit organization, ovarian cancer affected 313,959 women worldwide in 2020. This will have increased by 42% by 2040 to 445,721; between 2020 and 2040, there will be a 51% increase in the number of women dying from ovarian cancer, from 207,252 to 313,617. Therefore, the rising prevalence of ovarian cancer is driving the growth of the ovarian cancer diagnosis market.

Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=12022&type=smp

The ovarian cancer diagnostics market covered in this report is segmented –

1) By Product Type: Instruments, Kits, Reagents
2) By Diagnosis Type: Biopsy, Blood Test, Imaging, Other Diagnosis Types
3) By Cancer Type: Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor, Other Cancer Types
4) By End User: Cancer Diagnostic Centers, Hospital Laboratories, Research Institutes

Advanced diagnostic technology is a key trend gaining popularity in the ovarian cancer diagnostics market. Companies operating in the ovarian cancer diagnostic market are adopting advanced diagnostic technologies to sustain their position in the market. For instance, in November 2022, Hoffmann-La Roche AG, a Switzerland-based pharmaceutical and healthcare company, received FDA approval for the VENTANA FOLR1 (FOLR1-2.1) RxDx Assay, the first (immunohistochemistry) IHC-based companion diagnostic test kit for the identification of ovarian cancer patients eligible for ELAHERE, which is a prescription medication for ovarian cancer. This test is specifically designed to get critical insights and obtain detailed clinical information about the ovarian cancer condition, which helps deliver improved disease management and patient outcomes.

The ovarian cancer diagnostics market report table of contents includes:

1. Executive Summary
2. Market Characteristics
3. Market Trends And Strategies
4. Impact Of COVID-19
5. Market Size And Growth
6. Segmentation
7. Regional And Country Analysis
.
.
.
27. Competitive Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis

Major Players: 

  • F. Hoffmann-La Roche Ltd
  • Thermo Fisher Scientific Inc.
  • AstraZeneca PLC
  • Abbott Laboratories
  • Abbott Laboratories

Related Reports:

https://goodprnews.com/glycol-market-size-share-trends-report/
https://goodprnews.com/glycomic-therapeutics-market-forecast/
https://topprnews.com/glycol-market-size-share-report-forecast/
https://topprnews.com/glycomic-therapeutics-market-insights/

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Login

Welcome to WriteUpCafe Community

Join our community to engage with fellow bloggers and increase the visibility of your blog.
Join WriteUpCafe